Metoclopramide Accord (Metoclopramide Hydrochloride)

The drug blocks dopamine D2 receptors in the brain's chemoreceptor trigger zone and throughout the gastrointestinal tract, which reduces nausea signals and stimulates gastric motility. It also weakly blocks serotonin 5‑HT3 receptors and activates 5‑HT4 receptors, further supporting its anti‑emetic and pro‑kinetic actions.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Typical adult regimens range from 5 mg to 10 mg taken before meals, but exact dosing must be individualized by a healthcare professional.

Safety data in pregnancy and lactation are limited. The medication should be used only if the potential benefit justifies any possible risk to the fetus or infant, and it is generally prescribed after careful risk‑benefit assessment by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from agents such as domperidone by acting centrally on dopamine receptors as well as peripherally on gastrointestinal motility. While both improve gastric emptying, metoclopramide’s central action makes it effective for chemotherapy‑induced nausea, but it carries a higher risk of extrapyramidal side effects.

Store the product at room temperature below 25 °C, in its original packaging, and protect it from moisture. Keep it out of reach of children and avoid exposure to direct sunlight or extreme heat.

Metoclopramide Accord is taken orally, usually with a glass of water. It is often administered 30 minutes before meals and at bedtime when prescribed for gastric motility disorders. Follow the prescribing clinician’s instructions regarding timing and whether it should be taken with food.

The most concerning adverse events include extrapyramidal reactions such as dystonia or parkinsonism, tardive dyskinesia with prolonged use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, and rare anaphylactic reactions. Patients should be monitored closely for these signs.

Metoclopramide should be avoided in individuals with known hypersensitivity to the drug, in patients with Parkinson’s disease or other movement disorders, in those with uncontrolled epilepsy, and in patients who have experienced severe extrapyramidal reactions previously.